本帖最后由 老马 于 2013-3-13 13:43 编辑 }7 G% B9 a4 @# T
! v" g' t% v8 s6 i% Y( [2 j健择（吉西他滨）+顺铂+阿瓦斯汀
, Y6 ~; B- t) B, o( x Gemzar +Cisplatin + Avastin
/ J/ Y$ u2 t3 u0 ]http://annonc.oxfordjournals.org/content/21/9/1804.full
* o8 f1 ]# d/ ROverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) . g5 o/ Y2 k r5 Q$ f' K/ x3 ?1 F0 `
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
4 G( G' y# Z$ H6 U3 V2 MResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
9 b r2 |. L: s/ _( \
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 967)
8 E. C" X7 b7 h& P, u华为网盘附件：9 \: m7 P$ U$ z6 e3 j
【华为网盘】ava.JPG
+ N3 Y1 F7 t, E$ ` |
显身卡
